Hepatitis C News and Research

Latest Hepatitis C News and Research

Three-drug cocktail more effective against hepatitis C virus

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Could HIV-infected organs save 'lives?

Johns Hopkins researchers argue for reversing ban on transplanting infected organs and making them available to HIV-infected patients

30 Mar 2011

Pharmasset commences PSI-7977 Phase 2b study against HCV

Pharmasset, Inc. announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C.

30 Mar 2011

Los Alamos National Lab, Biomagnetics to develop and commercialize IOBS system

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced further details in next steps to be taken toward full commercialization of the Company's flagship Integrated Optical Biosensor diagnostic system.

30 Mar 2011

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A inhibitor for the treatment of patients with chronic hepatitis C.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Smoking cessation after liver transplantation reduces incidence of malignancy

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies (SRM) than patients who keep smoking. In fact, SRMs were identified in 13.5% of deceased patients and smoking was associated with a higher risk of malignancy in this study. Full findings are published in the April issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2011

Chembio develops DPP assay for rapid detection of HIV and HEP B/C

A kidney recipient in a New York City hospital recently contracted HIV from the transplanted organ, which came from a living donor, according to the New York State Department of Health. Although an initial screening had been performed on the donor, he or she apparently had unsafe sex after the test but before donating the kidney.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

XTL announces MinoGuard acquisition

XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd. by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

25 Mar 2011

Biostar fourth quarter revenues increase 65.7% to $28.2 million

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results for the fourth quarter and full year ended December 31, 2010.

25 Mar 2011

Researchers identify gene that can predict hypersensitivity to epilepsy drug

Research published this week in the New England Journal of Medicine. A multinational team of scientists led by the Royal College of Surgeons in Ireland and the University of Liverpool has identified a gene that could indicate if epilepsy patients starting a common drug treatment are likely to experience side-effects ranging from a mild skin irritation to the potentially fatal Steven-Johnson Syndrome.

25 Mar 2011

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

BUSM professors highlight increased risks of naturally occurring infections

Paul Duprex, PhD, and Elke M-hlberger, PhD, both associate professors of microbiology at Boston University School of Medicine, recently co-authored a commentary about viruses for Microbiology Today, the monthly publication of the Society of General Microbiology, which is the largest microbiological society in Europe.

19 Mar 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Three-drug cocktail more effective against hepatitis C virus

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Could HIV-infected organs save 'lives?

Pharmasset commences PSI-7977 Phase 2b study against HCV

Los Alamos National Lab, Biomagnetics to develop and commercialize IOBS system

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Smoking withdrawal after liver transplantation may protect against neoplasia development

Positive results from Vertex VX-770 Phase 3 trial against CF

Smoking cessation after liver transplantation reduces incidence of malignancy

Chembio develops DPP assay for rapid detection of HIV and HEP B/C

BMY receives FDA approval for YERVOY to treat metastatic melanoma

XTL announces MinoGuard acquisition

Biostar fourth quarter revenues increase 65.7% to $28.2 million

Researchers identify gene that can predict hypersensitivity to epilepsy drug

MicroRNAs may play a key role in future medicine

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

BUSM professors highlight increased risks of naturally occurring infections

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in